|
|
Article: Lexicon Genetics Announces Milestone in LexVision(TM) Collaboration With Bristol-Myers Squibb.
- Article from:
- PR Newswire
- Article date:
- January 8, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
THE WOODLANDS, Texas, Jan. 8 /PRNewswire/ --
Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has delivered to Bristol-Myers Squibb Company (NYSE: BMY) its first installment of the LexVision (TM) database containing gene function information for potential new drug targets. This installment, which was delivered prior to year-end 2000, triggered the initial quarterly payment from Bristol-Myers Squibb for its first year of access to LexVision.
"We are very pleased with the data that Lexicon's technology has generated for LexVision," stated James R. Piggott, Ph.D., Senior Vice President of Pharmaceutical Biology at Lexicon Genetics. ...